Watch 5:44
Conn. attorney general calls generic drug makers a ‘private sector cartel’
Affordable health care is a persistent concern for Americans and a topic of great political debate. Typically, generic prescription drugs offer a cheaper alternative to name brands, but a new multi-state lawsuit alleges that their manufacturers have been artificially raising…
Watch 4:20
How generic drug makers are responding to price-fixing lawsuit
U.S. consumers often turn to generic versions of prescription drugs to keep costs down, but dozens of states are now suing manufacturers of these drugs, saying they illegally fixed prices and divided up market share. Affected drugs include medicines used…
Mylan CEO defends EpiPen cost to angry lawmakers
The head of pharmaceutical company Mylan is defending the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers.
Watch 7:41
Did outcry on social media lead to Mylan’s generic EpiPen?
After news broke that the price of EpiPen injectors has skyrocketed, the allergy medicine’s maker, Mylan, announced its intention to offer a generic version of the product, to be sold at half the market price of the original. The New…
The Federal Trade Commission's recent $1.2 billion settlement over the drug Provigil has brought so-called "pay for delay" deals for generic drugs back into the spotlight. Opponents say these deals delay generic medications to market, costing consumers billions. But drug…
Pharmaceutical maker Teva has agreed to a settlement of $512 million in a class action lawsuit over the wakefulness drug Provigil. Drug wholesalers and retailers claimed a generic version of the drug was delayed to market by so-called “pay for…
The Food and Drug Administration has approved the first biosimilar drug for distribution in the United States, the agency announced on Friday.
We all know generics are cheaper. But how much cheaper? Economists find a 38 to 48 percent decline in the prices of physician-administered drugs after the drugs' patents have expired. The decline is slightly lower for oral drugs.
Americans are a small step closer to accessing less-expensive specialty drugs known as biologics. The Food and Drug Administration for the first time accepted an application for the approval of a copycat “generic” version of the brand name drug Neupogen,…
Additional Support Provided By:
